Dr. Arjun Balar is the director of the genitourinary medical oncology program at NYU Langone’s Perlmutter Cancer Center and is an assistant professor in the department of medicine at the NYU School of Medicine. Dr. Balar currently oversees outpatient clinical services for patients with prostate, kidney, bladder, and testicular cancers. His areas of research include bladder cancer, immunotherapy, and molecularly targeted therapy, with a specific focus on cisplatin-ineligible patients in the hopes of identifying better-tolerated and more effective therapies in advanced and invasive/high-grade urothelial cancer. Findings from Dr. Balar’s research have led to accelerated FDA approval of two drugs for advanced bladder cancer: pembrolizumab (Keytruda®) and atezolizumab (TECENTRIC®).